Cytosorbents (CTSO) EBITDA Margin Growth (5y) (2016 - 2026)
Cytosorbents (CTSO) EBITDA Margin Growth (5y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.39 Bn | 175.10 Bn | 6.27 Bn |
| 2 | Stryker | 128.75 Bn | 125.87 Bn | 3.81 Bn |
| 3 | Medtronic | 108.59 Bn | 99.37 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.22 Bn | 66.77 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 47.59 Bn | 43.92 Bn | 1.29 Bn |
| 6 | Dexcom | 28.58 Bn | 27.46 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.48 Bn | 26.20 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.96 Bn | 26.39 Bn | - |
| 9 | Koninklijke Philips | 25.47 Bn | 22.34 Bn | 2.07 Bn |
| 10 | Cytosorbents | 23.46 Mn | 18.66 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -743.00 |
| Dec 31, 2025 | -2,545.00 |
| Sep 30, 2025 | -1,159.00 |
| Jun 30, 2025 | -392.00 |
| Mar 31, 2025 | -1,608.00 |
| Dec 31, 2024 | 3,600.00 |
| Sep 30, 2024 | 3,625.00 |
| Jun 30, 2024 | 1,787.00 |
| Mar 31, 2024 | 3,074.00 |
| Dec 31, 2023 | -1,669.00 |
| Sep 30, 2023 | -3,622.00 |
| Jun 30, 2023 | 314.00 |
| Mar 31, 2023 | -2,054.00 |
| Dec 31, 2022 | 1,420.00 |
| Sep 30, 2022 | -5,497.00 |
| Jun 30, 2022 | -3,301.00 |
| Mar 31, 2022 | -3,962.00 |
| Dec 31, 2021 | 5,954.00 |
| Sep 30, 2021 | 3,352.00 |
| Jun 30, 2021 | 7,997.00 |